[Pharmacokinetic studies on plasma elimination half-life of oxipurinol (author's transl)].
In a randomized cross-over study with 10 volunteers two different commercial preparations of allopurinol (Remid and standard) were tested by reversed-phase HPLC with respect to their pharmacokinetic behaviour. After a single p.o. dose of 300 mg allopurinol plasma elimination half-life of the major metabolite oxipurinol was found to be about 40 h with both preparations, calculated from the course of the plasma levels. This result confirms that a single daily dose of 300 mg allopurinol in non-retard formulation supports therapeutically sufficient circadian plasma levels.
D000328:Adult; D000493:Allopurinol / Q000097:blood; D005260:Female; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008297:Male; D010117:Oxypurinol / Q000097:blood*; D011743:Pyrimidines / Q000097:blood*; D013997:Time Factors
D011743:Pyrimidines; D000493:Allopurinol; D010117:Oxypurinol
Pharmakokinetische Untersuchungen zur Plasma-Eliminationshalbwertszeit von Oxipurinol.